Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate - Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults

Home > Science Hub > Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate - Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults
Back to the list

June 5, 2019

Pillet S et al. PLoS One 2019;14(6):e0216533.

Immunogenicity and Safety of a Quadrivalent Plant-derived Virus Like Particle Influenza Vaccine Candidate – Two Randomized Phase II Clinical Trials in 18 to 49 and ≥50 Years Old Adults

Download publication

You might also be interested by

Brochures

Cell Therapy

December 15, 2023

Histopathology

More info

Infographics

Next-Generation Flow Cytometry Analysis with CellEngine™

January 31, 2023

Immune Monitoring

More info

CellTalk Blog

Discover Metadata-Driven Cytometry Analysis With CellEngine™

January 31, 2023

Immune Monitoring

More info

CellTalk Blog

Easy, Customized Autogating With CellEngine™

December 14, 2022

Immune Monitoring

More info